. Author manuscript; available in PMC: 2012 Jan 1.

Published in final edited form as: J Androl. 2010 Aug 26;32(1):40–48. doi: 10.2164/jandrol.110.010983

Table 2.

Changes in the lipid profiles during treatment with isoflavones.

Variable		Baseline	6 weeks	12 weeks	p-values
Total cholesterol (mg/dl)	Placebo	186.8 (13.08)	193.93 (10.74)	190.69 (11.66)	0.91
Total cholesterol (mg/dl)	Active	207.33 (12.45)	206.2 (12.64)	211.6 (11.91)	0.948
p-value		0.265	0.466	0.224
Triglycerides (mg/dl)	Placebo	129.33 (16.85)	119.4 (16.36)	130.15 (23.74)	0.903
Triglycerides (mg/dl)	Active	123.6 (7.97)	128.93 (9.63)	119.87 (11.55)	0.807
p-value		0.761	0.619	0.688
HDL cholesterol (mg/dl)	Placebo	55.47 (3.46)	56.4 (3.37)	56.92 (4.15)	0.96
HDL cholesterol (mg/dl)	Active	55.33 (2.93)	56 (3.06)	57.93 (3.46)	0.833
p-value		0.977	0.931	0.852
LDL cholesterol (mg/dl)	Placebo	114.27 (9.35)	113.67 (8.51)	107.77 (8.54)	0.856
LDL cholesterol (mg/dl)	Active	127.2 (10.65)	124.33 (11.13)	129.67 (10.09)	0.939
p-value		0.369	0.453	0.116
Total Cholesterol/HDL ratio	Placebo	3.6 (0.22)	3.57 (0.23)	3.52 (0.31)	0.978
Total Cholesterol/HDL ratio	Active	3.81 (0.22)	3.71 (0.2)	3.77 (0.25)	0.95
p-value		0.51	0.65	0.54